Additional Data on Provectus’s PV-10 for Metastatic Melanoma Presented at Prominent Melanoma Conferences
Additional Data on Provectus’s PV-10 for Metastatic Melanoma Presented at Prominent Melanoma Conferences
KNOXVILLE, Tenn.–(BUSINESS WIRE)–Provectus Pharmaceuticals announced that data and study design features on PV-10 for metastatic melanoma were presented at two separate conferences.
Read more on Business Wire
Categories: Breast Cancer Information Tags: Additional, Conferences, Data, Melanoma, Metastatic, presented, Prominent, Provectus’s, PV10
Enzon to discontinue PEG-SN38 clinical program in metastatic colorectal cancer
Enzon to discontinue PEG-SN38 clinical program in metastatic colorectal cancer
Enzon Pharmaceuticals, Inc. today announced that, in light of evolving standards of care for the treatment of metastatic colorectal cancer (mCRC), the Company will discontinue its PEG-SN38 (EZN-2208) clinical program in this disease, following conclusion of its Phase II study.
Read more on News-Medical-Net
Categories: Breast Cancer Treatment Tags: cancer, Clinical, Colorectal, discontinue, Enzon, Metastatic, PEGSN38, program
Metastatic Breast Cancer Stories
Conn Jackson interviews Fern Saitowitz, a woman diagnosed with Breast Cancer, and Dr. Anne Coscarelli about Metastatic Breast Cancer, which is stage 4 cancer. Fern tells her story about her diagnosis and the two women share their message that these women are not alone in their struggles.
Categories: Breast Cancer Treatment Tags: breast, cancer, Metastatic, stories.
Plexxikon’s PLX4032 shows positive data in patients with metastatic melanoma
Plexxikon’s PLX4032 shows positive data in patients with metastatic melanoma
Plexxikon today announced positive preliminary data from a pivotal Phase 2 clinical trial of PLX4032 (RG7204) in metastatic melanoma, showing significant tumor shrinkage in the majority of patients.
Read more on News-Medical-Net
Categories: Breast Cancer Tumor Tags: Data, Melanoma, Metastatic, Patients, Plexxikon's, PLX4032, positive, Shows
FDA approves Herceptin with chemotherapy for HER2-positive metastatic cancer
FDA approves Herceptin with chemotherapy for HER2-positive metastatic cancer
Genentech, a member of the Roche Group today announced the U.S. Food and Drug Administration (FDA) has approved Herceptin (trastuzumab) in combination with chemotherapy (cisplatin plus either capecitabine or 5-fluorouracil [5-FU]) for HER2-positive metastatic (cancer that has spread) cancer of the stomach or gastroesophageal junction, in men and women who have not received prior medicines for …
Read more on News-Medical-Net
Categories: High Risk Breast Cancer Tags: approves, cancer, Chemotherapy, HER2positive, Herceptin, Metastatic